1. Home
  2. BRO vs BIIB Comparison

BRO vs BIIB Comparison

Compare BRO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brown & Brown Inc.

BRO

Brown & Brown Inc.

HOLD

Current Price

$73.78

Market Cap

27.6B

Sector

Finance

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$201.18

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRO
BIIB
Founded
1939
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.6B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
BRO
BIIB
Price
$73.78
$201.18
Analyst Decision
Hold
Buy
Analyst Count
13
24
Target Price
$89.54
$181.77
AVG Volume (30 Days)
3.1M
1.6M
Earning Date
01-26-2026
02-06-2026
Dividend Yield
0.91%
N/A
EPS Growth
N/A
N/A
EPS
3.16
10.97
Revenue
$5,763,000,000.00
$10,065,900,000.00
Revenue This Year
$28.13
$3.60
Revenue Next Year
$7.07
N/A
P/E Ratio
$23.00
$16.89
Revenue Growth
22.30
4.77
52 Week Low
$70.45
$110.04
52 Week High
$125.68
$190.20

Technical Indicators

Market Signals
Indicator
BRO
BIIB
Relative Strength Index (RSI) 40.13 64.98
Support Level $70.45 $176.19
Resistance Level $75.28 $187.73
Average True Range (ATR) 2.17 4.55
MACD -0.31 1.43
Stochastic Oscillator 27.91 98.43

Price Performance

Historical Comparison
BRO
BIIB

About BRO Brown & Brown Inc.

Brown & Brown Inc is a diversified insurance agency, wholesale brokerage, insurance programs, and service. The Company markets and sells insurance products and services, in the property, casualty, and employee benefits areas. It provides customers with non-investment insurance contracts, as well as other targeted, customized risk management products and services. It has four reportable segments; the Retail segment; the Programs segment; the Wholesale Brokerage segment and; the Services segment. It generates the majority of its revenue from the Retail segment which provides insurance products and services to commercial, public and quasi-public, and Others through automobile dealer services F&I businesses. Its geographic area is U.S., U.K., the Republic of Ireland, Canada, and Others.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: